Treatment of latent tuberculosis infection;Traitement des infections tuberculeuses latentes

Revue des Maladies Respiratoires

Volumn 29, Issue 4, 2012, Pages 579-600

  Fraisse, P ^a  

^a HÔPITAL CIVIL   (France)

Author keywords

Latent tuberculosis infection; Preventive treatment; Prophylaxis; Tuberculosis

Indexed keywords

HEALTH EDUCATION; HUMAN; LATENT TUBERCULOSIS; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 84863618479     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.07.011     Document Type: Review

References (120)

1. Fraisse P. Diagnostic des infections tuberculeuses latentes (sujets sains, sujets immunodéprimés ou amenés à l'être). Rev Mal Resp. doi:10.1016/j.rmr.2011.05.019, à paraître.
2. Zumla A, Atun R, Maeurer M, et al. Viewpoint: scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 2011;16: 79-83.
3. Wilkinson KA, Kon OM, Newton SM, et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 2006;193:354-9. (Pubitemid 43122334)
4. Lincoln EM. The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 1954;69:682-9.
5. Ferebee S, Mount FW, Anastasiades A. Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report. Am Rev Tuberc 1957;76:942-63.
6. Comstock GW, Baum C, Snider Jr DE. Isoniazid prophylaxis among alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.
7. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28- 106.
8. International Union Against Tuberculosis Commitee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-64.
9. Smieja M, Marchetti C, Cook D, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000:CD001363, doi:10.1002/14651858.CD001363.
10. Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong chest service/tuberculosis research centre, Madras/British medical research council. Am Rev Respir Dis 1992;145:36-41.
11. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. (Pubitemid 40381339)
12. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-70. (Pubitemid 44455169)
13. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004;170:832-5. (Pubitemid 39346476)
14. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979;76:771-81.
15. Deschildre A, Poirier C, Cadranel J. Dans quelles circonstances et comment traiter une infection tuberculeuse latente ? Rev Mal Respir 2004;21:3S25-23S34.
16. Société de pneumologie de langue française. Recommandations de la société de pneumologie de langue française pour la prise en charge de la tuberculose en france. Rev Mal Respir 2004;21:3S1-104S.
17. Conseil supérieur d'hygiène publique de France. Prévention et prise en charge de la tuberculose en france. Synthèse et recommandations du groupe de travail du CSHPF (2002-2003). Rev Mal Resp 2003;20:7S3-106S.
18. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997;155: 1735-8. (Pubitemid 27216686)
19. Conseil supérieur d'hygiène publique de France. Avis du conseil supérieur d'hygiène publique de france section maladies transmissibles relatif au traitement de la tuberculose-infection (séance du 14 mars 2003). 2003.
20. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn community programs for clinical research on aids, the adult AIDS clinical trials group, the Pan American Health organization, and the Centers for disease control and prevention study group. JAMA 2000;283:1445-50. (Pubitemid 30151823)
21. Gao XF, Wang L, Liu GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006;10: 1080-90. (Pubitemid 44519344)
22. Centers for Disease Control Prevention (CDC), Society. AT. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:535-9.
23. Salpeter SR, Sanders GD, Salpeter EE, et al. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-61. (Pubitemid 28012074)
24. Colice GL, Decision analysis. public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990;150:2517-22.
25. Tsevat J, Taylor WC, Wong JB, et al. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 1988;137:215-20. (Pubitemid 18032856)
26. Pitman R, Jarman B, Coker R. Tuberculosis transmission and the impact of intervention on the incidence of infection. Int J Tuberc Lung Dis 2002;6:485-91. (Pubitemid 34601864)
27. Cattamanchi A, Hopewell PC, Gonzalez LC, et al. A 13- year molecular epidemiological analysis of tuberculosis in San Francisco. Int J Tuberc Lung Dis 2006;10:297- 304.
28. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-510.
29. Ferebee SH. Long-term effects of isoniazid prophylaxis. Bull Int Union Tuberc 1968;41:161-6.
30. Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. JAMA 1984;251:1283-5. (Pubitemid 14195205)
31. Veening GJ. Long-term isoniazid prophylaxis. Controlled trial on inh prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc 1968;41:169-71.
32. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71. (Pubitemid 28136204)
33. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. (Pubitemid 47378885)
34. Salinas C, Pascual Erquicia S, Diez R, et al. Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection. Med Clin (Barc) 2010;135:293-9.
35. Jasmer RM, Snyder DC, Chin DP, et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med 2000;162:1648-52.
36. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997;11:875-82. (Pubitemid 27226410)
37. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in hiv infection in Zambia. AIDS 1998;12:2447-57. (Pubitemid 28558603)
38. Fitzgerald DW, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001;28:305-7. (Pubitemid 33055460)
39. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011;365:21-31.
40. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20.
41. Nardell E, Churchyard G. What is thwarting tuberculosis prevention in high-burden settings? N Engl J Med 2011;365:79-81.
42. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010:CD000171, doi:10.1002/14651858.CD000171.pub3.
43. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Bmj 2007;334:136.
44. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in ugandan adults infected with the human immunodeficiency virus. Uganda-case western reserve university research collaboration. N Engl J Med 1997;337:801-8. (Pubitemid 27391629)
45. van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. Aids 2010;24:1051-5.
46. Rivero A, Lopez-Cortes L, Castillo R, et al. Randomized trial of three regimens to prevent tuberculosis in HIVinfected patients with anergy. Enferm Infecc Microbiol Clin 2003;21:287-92. (Pubitemid 36869935)
47. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010;182:1080-5.
48. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363:257-65.
49. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007;45:1518- 21. (Pubitemid 351411886)
50. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in south africa: a prospective cohort. AIDS 2009;23: 631-6.
51. Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-6.
52. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon- γ release assays and conventional screening tests before tumour necrosis factor-α blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5.
53. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60:1884-94.
54. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBnet consensus statement. Eur Respir J 2010;36:1185-206.
55. Cagatay T, Aydin M, Sunmez S, et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int 2010;30:1459-63.
56. Zabana Y, Domenech E, San Roman AL, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008;14:1387-91.
57. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57: 756-61. (Pubitemid 46932080)
58. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32. (Pubitemid 44519351)
59. McNab BD, Marciniuk DD, Alvi RA, et al. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in canadian plains Aborigines. Am J Respir Crit Care Med 2000;162:989-93.
60. Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9. (Pubitemid 35417777)
61. Fraser A, Paul M, Attamna A, et al. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006:CD005435, doi:10.1002/14651858.CD005435.pub2.
62. Sneag DB, Schaaf HS, Cotton MF, et al. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J 2007;26:1142-6. (Pubitemid 350190948)
63. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109:765-71. (Pubitemid 34493340)
64. Feja K, McNelley E, Tran CS, et al. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York city from 1995 to 2003. Pediatr Infect Dis J 2008;27:907-12.
65. Centers for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992;41:61-71.
66. Horn DL, Hewlett Jr D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330:1241. (Pubitemid 24122002)
67. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002;167:131-6. (Pubitemid 34791519)
68. Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005;26:462-4. (Pubitemid 41264210)
69. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: an european consensus. Eur Respir J 2010;36:925-49.
70. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50. (Pubitemid 29488035)
71. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazidassociated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972;106:357-65.
72. Kopanoff DE, Snider Jr DE, Caras GJ. Isoniazid-related hepatitis: a U.S. public health service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001. (Pubitemid 8380195)
73. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8. (Pubitemid 29143893)
74. Stead WW, To T, Harrison RW, et al. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987;107:843-5. (Pubitemid 18014235)
75. Comstock GW. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA 1986;256:2729-30 (Pubitemid 17178094)
76. Smith BM, Schwartzman K, Bartlett G, et al. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ 2011;183:E173-9.
77. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99:465-71.
78. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-7. (Pubitemid 37046873)
79. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-23. (Pubitemid 40994462)
80. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973;79:1-12.
81. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010;14:1374-81.
82. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry beirn community programs for clinical research on aids. N Engl J Med 1997;337:315-20. (Pubitemid 27318993)
83. Haroon M, Martin U, Devlin J. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int 2012;32:33-7.
84. Vanhoof J, Landewe S, Van Wijngaerden E, et al. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003;62:1241-2. (Pubitemid 37500639)
85. Yéni P. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. 2010: 418.
86. Jafri SM, Singal AG, Kaul D, et al. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl 2011;17:306-14.
87. Castro KG, Jereb JA, Koppaka VR, et al. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest 2003;123:967. (Pubitemid 36315526)
88. Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011;43:482-6.
89. Cattamanchi A, Dantes RB, Metcalfe JZ, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009;48:179-85.
90. Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12:744-51. (Pubitemid 43726847)
91. Bock NN, Metzger BS, Tapia JR, et al. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999;159:295-300. (Pubitemid 29036538)
92. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000;162:2033-8. (Pubitemid 32051659)
93. Li J, Munsiff SS, Tarantino T, et al. Adherence to treatment of latent tuberculosis infection in a clinical population in New York city. Int J Infect Dis 2010;14:e292-7.
94. Antonucci G, Girardi E, Raviglione M, et al. Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. Gista (gruppo italiano di studio tubercolosi e AIDS). Eur Respir J 2001;18:369-75. (Pubitemid 32776415)
95. Diaz A, Diez M, Bleda MJ, et al. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010;10:267.
96. Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis 2010;14:701-7.
97. MacIntyre CR, Ansari MZ, Carnie J, et al. No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in southeast asian refugees and migrants: completion and compliance are major determinants of effectiveness. Prev Med 2000;30:425-32. (Pubitemid 30252829)
98. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010;15:603-22.
99. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005;26:465-73. (Pubitemid 41264211)
100. Leung CC, Yew WW, Chang KC, et al. Risk of active tuberculosis among schoolchildren in Hong Kong. Archiv Pediatr Adolesc Med 2006;160:247-51.
101. Holland DP, Sanders GD, Hamilton CD, et al. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055-60.
102. Aspler A, Long R, Trajman A, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010;65:582-7.
103. Conseil supérieur d'hygiène publique de France. Enquêtes autour d'un cas de tuberculose. Avis du CSHPF 24-3-06 2006.
104. Conseil supérieur d'hygiène publique de France. Recommandations relatives à la lutte antituberculeuse chez les migrants en france. Séance du 30 septembre 2005, 10p.
105. AFSSAPS. Recommandations nationales. Prévention et prise en charge des tuberculoses survenant sous anti-tnf- α. Consultable sur www.afssaps.sante.fr. Juillet 2005, 6p.
106. Haute autorité de santé. Test de détection de la production d'interféron gamma pour le diagnostic des infections tuberculeuses. http://www.has-sante.fr/portail/upload/ docs/application/pdf/ rapport detection de linterferongamma. pdf. Décembre 2006, 50p.
107. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26. (Pubitemid 43235123)
108. Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents 2007;30:477-86. (Pubitemid 350051772)
109. Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The gruppo italiano di studio tubercolosi e AIDS (gista). JAMA 1995;274:143-8.
110. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50. (Pubitemid 19070537)
111. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The pulmonary complications of HIV infection study group. Ann Intern Med 1997;126:123-32.
112. Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the united states, 1998-2000. Am J Transplant 2004;4:1523-8. (Pubitemid 39159068)
113. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. (Pubitemid 350294226)
114. Ergun I, Ekmekci Y, Sengul S, et al. Mycobacterium tuberculosis infection in renal transplant recipients. Transplant Proc 2006;38:1344-5.
115. Bravo C, Roldan J, Roman A, et al. Tuberculosis in lung transplant recipients. Transplantation 2005;79:59-64. (Pubitemid 40140001)
116. Winthrop KL, Kubak BM, Pegues DA, et al. Transmission of Mycobacterium tuberculosis via lung transplantation. Am J Transplant 2004;4:1529-33. (Pubitemid 39159069)
117. Ahmed AT, Karter AJ. Tuberculosis in California dialysis patients. Int J Tuberc Lung Dis 2004;8:341- 5. (Pubitemid 38624871)
118. Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65:557-70.
119. Programme national de lutte antituberculeuse. http://www.sante.gouv.fr/ htm/dossiers/tuberculose/dossierde presseprogramme-national-lutte-contre- tuberculose20070711.pdf2007.
120. Haute autorité de santé. Guide affection de longue durée. Tuberculose active. 2007: 24p.